{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T21:36:37Z","timestamp":1783460197787,"version":"3.55.0"},"reference-count":59,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100025310","name":"National Centre for Clinical Research on Emerging Drugs","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100025310","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003921","name":"Australian Department of Health and Aged Care","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,1,17]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Methamphetamine use disorder is a global public health concern with no approved pharmacotherapies for its treatment. One recent randomised controlled trial conducted in the USA examined a combination of bupropion and naltrexone not readily available globally. Here, we report a trial protocol for an oral formulation of combined naltrexone and bupropion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This single-arm, open-label pilot study will assess the safety and feasibility of oral naltrexone and bupropion (40\u2009mg\/450\u2009mg daily in divided doses) in adults with methamphetamine use disorder. Participants (n=20) will be outpatients of a stimulant treatment program at an inner-city hospital in Sydney, Australia. The primary endpoint is Day 84. Participants will attend weekly study visits from Baseline to Week 12 and a follow-up telephone visit at Week 16. All participants will receive treatment as usual, such as psychosocial therapy. Primary outcomes are safety (measured by treatment-emergent adverse events (AEs)\/adverse reactions) and feasibility (measured by the time taken to recruit, the proportion of ineligible participants, retention in the study and study medication adherence). Secondary outcomes will assess methamphetamine use, craving and withdrawal; treatment goals and expectations; physical and psychological well-being; depression and anxiety; and treatment satisfaction. Qualitative interviews will assess the acceptability of the intervention and outcome measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study received ethics approval from the St Vincent\u2019s Hospital Human Research Ethics Committee (2023\/ETH00549). Results will be submitted to peer-reviewed journals and scientific conferences, and a video abstract will be created to ensure that the findings are accessible to participants and people who use methamphetamines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ANZCTR: ACTRN12623000866606 (protocol V.2.1 dated 08 April 2024).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-092032","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T22:58:36Z","timestamp":1738969116000},"page":"e092032","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Trial protocol of an open-label pilot study of oral naltrexone\u2013bupropion combination pharmacotherapy for the treatment of methamphetamine use disorder (the NABU trial)"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6534-3325","authenticated-orcid":false,"given":"Krista J","family":"Siefried","sequence":"first","affiliation":[{"name":"The National Centre for Clinical Research on Emerging Drugs (NCCRED), The University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia"},{"name":"The National Drug and Alcohol Research Centre (NDARC), The University of New South Wales, Randwick, New South Wales, Australia"},{"name":"New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), c\/o The Ministry of Health New South Wales, St Leonards, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2343-5504","authenticated-orcid":false,"given":"Liam","family":"Acheson","sequence":"additional","affiliation":[{"name":"The National Centre for Clinical Research on Emerging Drugs (NCCRED), The University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia"},{"name":"The National Drug and Alcohol Research Centre (NDARC), The University of New South Wales, Randwick, New South Wales, Australia"},{"name":"New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), c\/o The Ministry of Health New South Wales, St Leonards, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9178-9013","authenticated-orcid":false,"given":"Brendan","family":"Clifford","sequence":"additional","affiliation":[{"name":"The National Centre for Clinical Research on Emerging Drugs (NCCRED), The University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia"},{"name":"The National Drug and Alcohol Research Centre (NDARC), The University of New South Wales, Randwick, New South Wales, Australia"},{"name":"New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), c\/o The Ministry of Health New South Wales, St Leonards, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Moller","sequence":"additional","affiliation":[{"name":"The National Centre for Clinical Research on Emerging Drugs (NCCRED), The University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Brett","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Toxicology; and Psychiatric, Alcohol and Non-Prescription Drug Assessment Unit, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia"},{"name":"St Vincent's Clinical School, The University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Christmass","sequence":"additional","affiliation":[{"name":"Next Step Drug and Alcohol Services, East Metropolitan Health Service, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian John","family":"Dunlop","sequence":"additional","affiliation":[{"name":"New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), c\/o The Ministry of Health New South Wales, St Leonards, New South Wales, Australia"},{"name":"Drug and Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, New South Wales, Australia"},{"name":"School of Medicine and Public Health, The University of Newcastle, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S","family":"Haber","sequence":"additional","affiliation":[{"name":"New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), c\/o The Ministry of Health New South Wales, St Leonards, New South Wales, Australia"},{"name":"Faculty of Medicine and Health, Central Clinical School, Discipline of Addiction Medicine, University of Sydney, Sydney, New South Wales, Australia"},{"name":"Edith Collins Centre for Translational Research, Drug Health Services, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Jutras-Aswad","sequence":"additional","affiliation":[{"name":"Research Centre, Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CRCHUM), Montreal, Quebec, Canada"},{"name":"Department of Psychiatry and Addictology, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Lintzeris","sequence":"additional","affiliation":[{"name":"New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), c\/o The Ministry of Health New South Wales, St Leonards, New South Wales, Australia"},{"name":"Faculty of Medicine and Health, Central Clinical School, Discipline of Addiction Medicine, University of Sydney, Sydney, New South Wales, Australia"},{"name":"The Langton Centre, South Eastern Sydney Local Health District, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0868-9928","authenticated-orcid":false,"given":"Kirsten","family":"Morley","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, Central Clinical School, Discipline of Addiction Medicine, University of Sydney, Sydney, New South Wales, Australia"},{"name":"Edith Collins Centre for Translational Research, Drug Health Services, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Shoptaw","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of California Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhukar H","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Peter O'Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7495-8305","authenticated-orcid":false,"given":"Nadine","family":"Ezard","sequence":"additional","affiliation":[{"name":"The National Centre for Clinical Research on Emerging Drugs (NCCRED), The University of New South Wales, Sydney, New South Wales, Australia"},{"name":"Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia"},{"name":"The National Drug and Alcohol Research Centre (NDARC), The University of New South Wales, Randwick, New South Wales, Australia"},{"name":"New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), c\/o The Ministry of Health New South Wales, St Leonards, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"2025120519390275000_15.2.e092032.1","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/S0140-6736(19)32230-5","article-title":"Responding to global stimulant use: challenges and opportunities","volume":"394","author":"Farrell","year":"2019","journal-title":"Lancet"},{"key":"2025120519390275000_15.2.e092032.2","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.ajem.2018.01.001","article-title":"Methamphetamine use and heart failure: Prevalence, risk factors, and predictors","volume":"36","author":"Richards","year":"2018","journal-title":"Am J Emerg Med"},{"key":"2025120519390275000_15.2.e092032.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2013.12.025"},{"key":"2025120519390275000_15.2.e092032.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2018.01.021"},{"key":"2025120519390275000_15.2.e092032.5","article-title":"Psychosocial interventions for stimulant use disorder","volume":"2024","author":"Minozzi","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2025120519390275000_15.2.e092032.6","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00711-x"},{"key":"2025120519390275000_15.2.e092032.7","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1111\/add.16200","article-title":"Agreement between self-reported illicit drug use and biological samples: a systematic review and meta-analysis","volume":"118","author":"Bharat","year":"2023","journal-title":"Addiction"},{"key":"2025120519390275000_15.2.e092032.8","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) . Stimulant use disorders: developing drugs for treatment, guidance for industry: draft guidance. 2023."},{"key":"2025120519390275000_15.2.e092032.9","doi-asserted-by":"publisher","DOI":"10.1037\/a0030992"},{"key":"2025120519390275000_15.2.e092032.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2020214"},{"key":"2025120519390275000_15.2.e092032.11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/ADM.0000000000001299","article-title":"The ASAM\/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder","volume":"18","year":"2024","journal-title":"J Addict Med"},{"key":"2025120519390275000_15.2.e092032.12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2174\/1570159X15666170915142122","article-title":"Why are Antidepressant Drugs Effective Smoking Cessation Aids?","volume":"16","author":"Shoaib","year":"2018","journal-title":"Curr Neuropharmacol"},{"key":"2025120519390275000_15.2.e092032.13","doi-asserted-by":"publisher","DOI":"10.1177\/2045125316629071"},{"key":"2025120519390275000_15.2.e092032.14","doi-asserted-by":"crossref","first-page":"111018","DOI":"10.1016\/j.drugalcdep.2023.111018","article-title":"Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials","volume":"253","author":"Bakouni","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"2025120519390275000_15.2.e092032.15","unstructured":"Aspen Pharmacare Australia . Australian product information - Zyban SR (bupropion hydrochloride) sustained release tablets. 2022."},{"key":"2025120519390275000_15.2.e092032.16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300979"},{"key":"2025120519390275000_15.2.e092032.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2008.09.006"},{"key":"2025120519390275000_15.2.e092032.18","unstructured":"Center for Substance Abuse Treatment . Incorporating alcohol pharmacotherapies into medical practice. In: Treatment improvement protocol (TIP) series 49. HHS publication no. (SMA) 09-4380. Rockville (MD): Substance Abuse and Mental Health Services Administration, 2009."},{"key":"2025120519390275000_15.2.e092032.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2005.05.028"},{"key":"2025120519390275000_15.2.e092032.20","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/npp.2015.83","article-title":"The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study","volume":"40","author":"Ray","year":"2015","journal-title":"Neuropsychopharmacol"},{"key":"2025120519390275000_15.2.e092032.21","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1007\/s00213-017-4607-8","article-title":"Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder","volume":"234","author":"Roche","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"2025120519390275000_15.2.e092032.22","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101436","article-title":"The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy","volume":"49","author":"le Roux","year":"2022","journal-title":"EClinicalMed"},{"key":"2025120519390275000_15.2.e092032.23","first-page":"164","article-title":"Naltrexone\/bupropion ER (contrave): newly approved treatment option for chronic weight management in obese adults","volume":"41","author":"Sherman","year":"2016","journal-title":"Pharmacy Therapeu"},{"key":"2025120519390275000_15.2.e092032.24","unstructured":"Vivitrol price guide. Available: https:\/\/www.drugs.com\/price-guide\/vivitrol [Accessed 4 Feb 2025]."},{"key":"2025120519390275000_15.2.e092032.25","doi-asserted-by":"publisher","DOI":"10.1111\/imj.16159"},{"key":"2025120519390275000_15.2.e092032.26","unstructured":"Sahid A , Lintzeris N . Substance use recovery goals and expectations (SURGE) questionnaire. 2024."},{"key":"2025120519390275000_15.2.e092032.27","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583"},{"key":"2025120519390275000_15.2.e092032.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2015.04.014"},{"key":"2025120519390275000_15.2.e092032.29","doi-asserted-by":"publisher","DOI":"10.1002\/nur.20247"},{"key":"2025120519390275000_15.2.e092032.30","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.fertnstert.2024.01.040","article-title":"A brief overview of pilot studies and their sample size justification","volume":"121","author":"Kunselman","year":"2024","journal-title":"Fertil Steril"},{"key":"2025120519390275000_15.2.e092032.31","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.5.484"},{"key":"2025120519390275000_15.2.e092032.32","unstructured":"iNova Pharmaceuticals . Australian product information \u2013 contrave 8\/90 (naltrexone hydrochloride and bupropion hydrochloride) extended-release tablets. 2023."},{"key":"2025120519390275000_15.2.e092032.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2006.00052.x"},{"key":"2025120519390275000_15.2.e092032.34","unstructured":"US Food Drug Administration . WELLBUTRIN XL (bupropion hydrochloride extended-release tablets). Silver Spring, MD US Food and Drug Administration; 2011."},{"key":"2025120519390275000_15.2.e092032.35","doi-asserted-by":"crossref","unstructured":"O\u2019Brien ST , Dozo N , Hinton JDX , et al . SEMA3: a free smartphone platform for daily life surveys. 2023. Available: https:\/\/doi.org\/10.31234\/osf.io\/cnar8","DOI":"10.31234\/osf.io\/cnar8"},{"key":"2025120519390275000_15.2.e092032.36","first-page":"690","article-title":"Validation on the simplified medication adherence questionnaire (SMAQ) in renal transplant patients on tacrolimus","volume":"31","author":"Ortega Su\u00e1rez","year":"2011","journal-title":"Nefrologia"},{"key":"2025120519390275000_15.2.e092032.37","unstructured":"U.S. Department of Health and Human Services . Division of AIDS (DAIDS), table for grading the severity of adult and pediatric adverse events, corrected version 2.1. National Institute of Allergy and Infectious Diseases; 2017."},{"key":"2025120519390275000_15.2.e092032.38","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Annotated with TGA Comments . Integrated addendum to ICH E6(R1): guideline for good clinical practice ICH E6(R2). 2016. Available: https:\/\/admin.ich.org\/sites\/default\/files\/inline-files\/E6_R2__Addendum_Step2.pdf?utm_medium=email&utm_source=transaction"},{"key":"2025120519390275000_15.2.e092032.39","unstructured":"National Health and Medical Research Council . Guidance: safety monitoring and reporting in clinical trials involving therapeutic goods. Canberra, 2016."},{"key":"2025120519390275000_15.2.e092032.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025120519390275000_15.2.e092032.41","doi-asserted-by":"publisher","DOI":"10.1177\/0962280215588242"},{"key":"2025120519390275000_15.2.e092032.42","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s40814-019-0499-1","article-title":"Guidelines for reporting non-randomised pilot and feasibility studies","volume":"5","author":"Lancaster","year":"2019","journal-title":"Pilot Feasibility Stud"},{"key":"2025120519390275000_15.2.e092032.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2010.10.008"},{"key":"2025120519390275000_15.2.e092032.44","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40814-015-0026-y","article-title":"Maximising the impact of qualitative research in feasibility studies for randomised controlled trials: guidance for researchers","volume":"1","author":"O\u2019Cathain","year":"2015","journal-title":"Pilot Feasibility Stud"},{"key":"2025120519390275000_15.2.e092032.45","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-018-1842-3"},{"key":"2025120519390275000_15.2.e092032.46","doi-asserted-by":"publisher","DOI":"10.1177\/0163278711424282"},{"key":"2025120519390275000_15.2.e092032.47","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00132576-200211000-00005","article-title":"A Comparison of Single-Item Visual Analog Scales With a Multiitem Likert-Type Scale for Assessment of Cocaine Craving in Persons With Bipolar Disorder","volume":"1","author":"Lee","year":"2002","journal-title":"Addict Disord Their Treat"},{"key":"2025120519390275000_15.2.e092032.48","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1614.1999.00517.x"},{"key":"2025120519390275000_15.2.e092032.49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Heal Qual Life Outcomes"},{"key":"2025120519390275000_15.2.e092032.50","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.150.6.885"},{"key":"2025120519390275000_15.2.e092032.51","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/1099-0879(200011)7:5<401::AID-CPP253>3.0.CO;2-I","article-title":"The social support inventory (SSI): a brief scale to assess perceived adequacy of social support","volume":"7","author":"Timmerman","year":"2000","journal-title":"Clin Psychol Psychother"},{"key":"2025120519390275000_15.2.e092032.52","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"2025120519390275000_15.2.e092032.53","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/dar.13350","article-title":"A clinical research priority setting study for issues related to the use of methamphetamine and emerging drugs of concern in Australia","volume":"41","author":"Siefried","year":"2022","journal-title":"Drug Alcohol Rev"},{"key":"2025120519390275000_15.2.e092032.54","unstructured":"National Health and Medical Research Council . Payment of participants in research: information for researchers, HRECs and other ethics review bodies. Commonwealth of Australia, Canberra: Australian Research Council and Universities Australia, 2019."},{"key":"2025120519390275000_15.2.e092032.55","unstructured":"Ritchie J , Spencer L , O\u2019Connor W . Qualitative research practice: a guide for social science students and researchers. 2003."},{"key":"2025120519390275000_15.2.e092032.56","unstructured":"Australian Research Council and the Australian Vice-Chancellors\u2019 Committee . National statement on ethical conduct in human research 2007. Commonwealth of Australia, Canberra: National Health and Medical Research Council, 2015."},{"key":"2025120519390275000_15.2.e092032.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2008.03.010"},{"key":"2025120519390275000_15.2.e092032.58","unstructured":"American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 5th edn. 2016."},{"key":"2025120519390275000_15.2.e092032.59","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-10-1","article-title":"A tutorial on pilot studies: the what, why and how","volume":"10","author":"Thabane","year":"2010","journal-title":"BMC Med Res Methodol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-092032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T03:39:11Z","timestamp":1764992351000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-092032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,7]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bmjopen-2024-092032"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-092032","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}